{"id":294343,"date":"2024-06-26T00:00:00","date_gmt":"2024-06-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0024-2024-biopharma-myasthenia-gravis-current-treatment-current-treatment-physician-insights\/"},"modified":"2026-06-07T23:21:08","modified_gmt":"2026-06-07T23:21:08","slug":"cutrcg0024-2024-biopharma-myasthenia-gravis-current-treatment-current-treatment-physician-insights-myasthenia-gravis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0024-2024-biopharma-myasthenia-gravis-current-treatment-current-treatment-physician-insights-myasthenia-gravis\/","title":{"rendered":"Myasthenia Gravis &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Myasthenia Gravis (US)"},"content":{"rendered":"<p>Myasthenia gravis (<abbr title=\"myasthenia gravis\">MG<\/abbr>) is a rare neuromuscular disorder primarily caused by autoantibodies targeting acetylcholine (<abbr title=\"acetylcholine\">ACh<\/abbr>) receptors and therefore affecting neuromuscular synaptic transmission at the neuromuscular junction. It is a heterogenous disease, with generalized <abbr title=\"myasthenia gravis\">MG<\/abbr> characterized by the presence of autoantibodies for <abbr title=\"acetylcholine\">ACh<\/abbr> receptors; while a subset of <abbr title=\"myasthenia gravis\">MG<\/abbr> patients express other antibodies (e.g., anti-MuSK) or are seronegative. Its predominant manifestation is muscle weakness, particularly in limbs or respiratory muscles, although some patients exclusively experience ocular symptoms. Neurologists commonly treat <abbr title=\"myasthenia gravis\">MG<\/abbr> symptoms with acetylcholinesterase inhibitors (e.g., pyridostigmine), corticosteroids, and\/or immunosuppressants. Notably, the <abbr title=\"Food and Drug Administration\">FDA<\/abbr> has granted approval for five biologics in the treatment of <abbr title=\"myasthenia gravis\">MG<\/abbr>: eculizumab (Alexion \/ AstraZeneca\u2019s Soliris) in 2017, efgartigimod (Argenx\u2019s Vyvgart) in 2021, ravulizumab (Alexion \/ AstraZeneca\u2019s Ultomiris) in 2022, zilucoplan, and rozanolixizumab (UCB\u2019s Zilbrysq and Rystiggo, respectively) in 2023. Understanding the multifaceted decision points that neurologists encounter when treating <abbr title=\"myasthenia gravis\">MG<\/abbr> provides a valuable context for developers entering this evolving market. This report delves into neurologists&#8217; perceptions and opinions, offering a comprehensive analysis of the current <abbr title=\"myasthenia gravis\">MG<\/abbr> treatment landscape.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What percentage of <abbr title=\"myasthenia gravis\">MG<\/abbr> patients receive drug therapy and with what drugs \/ drug classes?<\/li>\n<li>How long do patients stay on a therapy? What do they switch to when they discontinue their current treatment?<\/li>\n<li>What are neurologists\u2019 preferred drugs \/ drug classes in each line of therapy, and why?<\/li>\n<li>What are neurologists\u2019 opinions of the recently approved drugs for <abbr title=\"myasthenia gravis\">MG<\/abbr>? How are neurologists incorporating these drugs into the treatment landscape?<\/li>\n<li>How and why has neurologists\u2019 prescribing changed in the past year? What changes are they anticipating in the coming year?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p><strong>Markets covered: <\/strong>United States<\/p>\n<p><strong>Key companies:<\/strong> Alexion \/ AstraZeneca, Argenx, UCB<\/p>\n<p><strong>Key drugs: <\/strong><abbr title=\"acetylcholinesterase inhibitor\">AChEI<\/abbr>s, corticosteroids, immunosuppressants, Rystiggo, Soliris, Ultomiris, Vyvgart, Zilbrysq<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n","protected":false},"template":"","class_list":["post-294343","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/294343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=294343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}